| Characteristics . | All . | SR . | AF . | P-values (AF vs. SR) . |
|---|---|---|---|---|
| n = 23 . | n = 16 . | n = 7 . | ||
| Age (years) | 76 ± 5 | 76 ± 5 | 76 ± 6 | 0.8667 |
| Male, n (%) | 23 (100) | 16 (100) | 7 (100) | 1.0000 |
| Hypertension, n (%) | 17 (74) | 12 (75) | 5 (71) | 1.0000 |
| Diabetes Mellitus, n (%) | 8 (34) | 4 (25) | 4 (57) | 0.1819 |
| Dyslipidaemia, n (%) | 6 (26) | 5 (31) | 1 (14) | 0.6214 |
| Obesity, n (%) | 4 (17) | 4 (25) | 0 (0) | 0.2727 |
| BMI (kg/m2) | 22.6 ± 2.5 | 22.8 ± 6 | 22.2 ± 1.6 | 0.5034 |
| NYHA class II, n (%) | 15 (65) | 12 (75) | 3 (43) | 0.1819 |
| NYHA class III, n (%) | 8 (35) | 4 (25) | 4 (57) | 0.1819 |
| SBP (mmHg) | 118 ± 20 | 124 ± 20 | 106 ± 14 | 0.0817 |
| DBP (mmHg) | 73 ± 14 | 76 ± 14 | 67 ± 11 | 0.1238 |
| Heart rate (/min) | 69 ± 9 | 67 ± 9 | 74 ± 8 | 0.0944 |
| Hb (g/dL) | 13.8 ± 1.2 | 14.3 ± 1.3 | 13.8 ± 1.2 | 0.4824 |
| eGFR (mL/min/1.73m2) | 46 ± 14 | 48 ± 11 | 43 ± 19 | 0.1923 |
| AST (IU/L) | 24 (19–27) | 24 (19–27) | 23 (17–31) | 0.9466 |
| ALT (IU/L) | 17 (10–19) | 17 (11–20) | 12 (9–18) | 0.2538 |
| CK (IU/L) | 94 (68–160) | 98 (70–167) | 71 (40–156) | 0.2421 |
| Hs-TnT (ng/mL) | 0.064 (0.042–0.099) | 0.062 (0.039–0.094) | 0.066 (0.053–0.105) | 0.4828 |
| LDL-C (mg/dL) | 92 ± 31 | 90 ± 30 | 99 ± 33 | 0.5697 |
| NT-proBNP (pg/mL) | 1898 (832–3291) | 1697 (762–1981) | 3533 (2284–7168) | 0.0177 |
| ACEi/ARB, n (%) | 11 (58) | 7 (48) | 4 (57) | 0.6668 |
| Beta blocker, n (%) | 15 (65) | 8 (50) | 7 (100) | 0.0520 |
| MRA, n (%) | 8 (34) | 6 (38) | 2 (29) | 1.0000 |
| Diuretics, n (%) | 11 (48) | 6 (38) | 5 (71) | 0.1930 |
| ARNI, n (%) | 2 (9) | 2 (13) | 0 (0) | 1.0000 |
| SGLT2I, n (%) | 5 (22) | 4 (25) | 1 (14) | 1.0000 |
| CCB, n (%) | 3 (13) | 0 (0) | 3 (19) | 0.5257 |
| Characteristics . | All . | SR . | AF . | P-values (AF vs. SR) . |
|---|---|---|---|---|
| n = 23 . | n = 16 . | n = 7 . | ||
| Age (years) | 76 ± 5 | 76 ± 5 | 76 ± 6 | 0.8667 |
| Male, n (%) | 23 (100) | 16 (100) | 7 (100) | 1.0000 |
| Hypertension, n (%) | 17 (74) | 12 (75) | 5 (71) | 1.0000 |
| Diabetes Mellitus, n (%) | 8 (34) | 4 (25) | 4 (57) | 0.1819 |
| Dyslipidaemia, n (%) | 6 (26) | 5 (31) | 1 (14) | 0.6214 |
| Obesity, n (%) | 4 (17) | 4 (25) | 0 (0) | 0.2727 |
| BMI (kg/m2) | 22.6 ± 2.5 | 22.8 ± 6 | 22.2 ± 1.6 | 0.5034 |
| NYHA class II, n (%) | 15 (65) | 12 (75) | 3 (43) | 0.1819 |
| NYHA class III, n (%) | 8 (35) | 4 (25) | 4 (57) | 0.1819 |
| SBP (mmHg) | 118 ± 20 | 124 ± 20 | 106 ± 14 | 0.0817 |
| DBP (mmHg) | 73 ± 14 | 76 ± 14 | 67 ± 11 | 0.1238 |
| Heart rate (/min) | 69 ± 9 | 67 ± 9 | 74 ± 8 | 0.0944 |
| Hb (g/dL) | 13.8 ± 1.2 | 14.3 ± 1.3 | 13.8 ± 1.2 | 0.4824 |
| eGFR (mL/min/1.73m2) | 46 ± 14 | 48 ± 11 | 43 ± 19 | 0.1923 |
| AST (IU/L) | 24 (19–27) | 24 (19–27) | 23 (17–31) | 0.9466 |
| ALT (IU/L) | 17 (10–19) | 17 (11–20) | 12 (9–18) | 0.2538 |
| CK (IU/L) | 94 (68–160) | 98 (70–167) | 71 (40–156) | 0.2421 |
| Hs-TnT (ng/mL) | 0.064 (0.042–0.099) | 0.062 (0.039–0.094) | 0.066 (0.053–0.105) | 0.4828 |
| LDL-C (mg/dL) | 92 ± 31 | 90 ± 30 | 99 ± 33 | 0.5697 |
| NT-proBNP (pg/mL) | 1898 (832–3291) | 1697 (762–1981) | 3533 (2284–7168) | 0.0177 |
| ACEi/ARB, n (%) | 11 (58) | 7 (48) | 4 (57) | 0.6668 |
| Beta blocker, n (%) | 15 (65) | 8 (50) | 7 (100) | 0.0520 |
| MRA, n (%) | 8 (34) | 6 (38) | 2 (29) | 1.0000 |
| Diuretics, n (%) | 11 (48) | 6 (38) | 5 (71) | 0.1930 |
| ARNI, n (%) | 2 (9) | 2 (13) | 0 (0) | 1.0000 |
| SGLT2I, n (%) | 5 (22) | 4 (25) | 1 (14) | 1.0000 |
| CCB, n (%) | 3 (13) | 0 (0) | 3 (19) | 0.5257 |
ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AST, aspartate aminotransferase; BMI, body mass index; CCB, calcium channel blocker; CK, creatine kinase; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; Hs-TnT, high-sensitivity troponin T; LDL-C, low-density lipoprotein cholesterol; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro–B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SGLT2, sodium-glucose co-transporter 2.
| Characteristics . | All . | SR . | AF . | P-values (AF vs. SR) . |
|---|---|---|---|---|
| n = 23 . | n = 16 . | n = 7 . | ||
| Age (years) | 76 ± 5 | 76 ± 5 | 76 ± 6 | 0.8667 |
| Male, n (%) | 23 (100) | 16 (100) | 7 (100) | 1.0000 |
| Hypertension, n (%) | 17 (74) | 12 (75) | 5 (71) | 1.0000 |
| Diabetes Mellitus, n (%) | 8 (34) | 4 (25) | 4 (57) | 0.1819 |
| Dyslipidaemia, n (%) | 6 (26) | 5 (31) | 1 (14) | 0.6214 |
| Obesity, n (%) | 4 (17) | 4 (25) | 0 (0) | 0.2727 |
| BMI (kg/m2) | 22.6 ± 2.5 | 22.8 ± 6 | 22.2 ± 1.6 | 0.5034 |
| NYHA class II, n (%) | 15 (65) | 12 (75) | 3 (43) | 0.1819 |
| NYHA class III, n (%) | 8 (35) | 4 (25) | 4 (57) | 0.1819 |
| SBP (mmHg) | 118 ± 20 | 124 ± 20 | 106 ± 14 | 0.0817 |
| DBP (mmHg) | 73 ± 14 | 76 ± 14 | 67 ± 11 | 0.1238 |
| Heart rate (/min) | 69 ± 9 | 67 ± 9 | 74 ± 8 | 0.0944 |
| Hb (g/dL) | 13.8 ± 1.2 | 14.3 ± 1.3 | 13.8 ± 1.2 | 0.4824 |
| eGFR (mL/min/1.73m2) | 46 ± 14 | 48 ± 11 | 43 ± 19 | 0.1923 |
| AST (IU/L) | 24 (19–27) | 24 (19–27) | 23 (17–31) | 0.9466 |
| ALT (IU/L) | 17 (10–19) | 17 (11–20) | 12 (9–18) | 0.2538 |
| CK (IU/L) | 94 (68–160) | 98 (70–167) | 71 (40–156) | 0.2421 |
| Hs-TnT (ng/mL) | 0.064 (0.042–0.099) | 0.062 (0.039–0.094) | 0.066 (0.053–0.105) | 0.4828 |
| LDL-C (mg/dL) | 92 ± 31 | 90 ± 30 | 99 ± 33 | 0.5697 |
| NT-proBNP (pg/mL) | 1898 (832–3291) | 1697 (762–1981) | 3533 (2284–7168) | 0.0177 |
| ACEi/ARB, n (%) | 11 (58) | 7 (48) | 4 (57) | 0.6668 |
| Beta blocker, n (%) | 15 (65) | 8 (50) | 7 (100) | 0.0520 |
| MRA, n (%) | 8 (34) | 6 (38) | 2 (29) | 1.0000 |
| Diuretics, n (%) | 11 (48) | 6 (38) | 5 (71) | 0.1930 |
| ARNI, n (%) | 2 (9) | 2 (13) | 0 (0) | 1.0000 |
| SGLT2I, n (%) | 5 (22) | 4 (25) | 1 (14) | 1.0000 |
| CCB, n (%) | 3 (13) | 0 (0) | 3 (19) | 0.5257 |
| Characteristics . | All . | SR . | AF . | P-values (AF vs. SR) . |
|---|---|---|---|---|
| n = 23 . | n = 16 . | n = 7 . | ||
| Age (years) | 76 ± 5 | 76 ± 5 | 76 ± 6 | 0.8667 |
| Male, n (%) | 23 (100) | 16 (100) | 7 (100) | 1.0000 |
| Hypertension, n (%) | 17 (74) | 12 (75) | 5 (71) | 1.0000 |
| Diabetes Mellitus, n (%) | 8 (34) | 4 (25) | 4 (57) | 0.1819 |
| Dyslipidaemia, n (%) | 6 (26) | 5 (31) | 1 (14) | 0.6214 |
| Obesity, n (%) | 4 (17) | 4 (25) | 0 (0) | 0.2727 |
| BMI (kg/m2) | 22.6 ± 2.5 | 22.8 ± 6 | 22.2 ± 1.6 | 0.5034 |
| NYHA class II, n (%) | 15 (65) | 12 (75) | 3 (43) | 0.1819 |
| NYHA class III, n (%) | 8 (35) | 4 (25) | 4 (57) | 0.1819 |
| SBP (mmHg) | 118 ± 20 | 124 ± 20 | 106 ± 14 | 0.0817 |
| DBP (mmHg) | 73 ± 14 | 76 ± 14 | 67 ± 11 | 0.1238 |
| Heart rate (/min) | 69 ± 9 | 67 ± 9 | 74 ± 8 | 0.0944 |
| Hb (g/dL) | 13.8 ± 1.2 | 14.3 ± 1.3 | 13.8 ± 1.2 | 0.4824 |
| eGFR (mL/min/1.73m2) | 46 ± 14 | 48 ± 11 | 43 ± 19 | 0.1923 |
| AST (IU/L) | 24 (19–27) | 24 (19–27) | 23 (17–31) | 0.9466 |
| ALT (IU/L) | 17 (10–19) | 17 (11–20) | 12 (9–18) | 0.2538 |
| CK (IU/L) | 94 (68–160) | 98 (70–167) | 71 (40–156) | 0.2421 |
| Hs-TnT (ng/mL) | 0.064 (0.042–0.099) | 0.062 (0.039–0.094) | 0.066 (0.053–0.105) | 0.4828 |
| LDL-C (mg/dL) | 92 ± 31 | 90 ± 30 | 99 ± 33 | 0.5697 |
| NT-proBNP (pg/mL) | 1898 (832–3291) | 1697 (762–1981) | 3533 (2284–7168) | 0.0177 |
| ACEi/ARB, n (%) | 11 (58) | 7 (48) | 4 (57) | 0.6668 |
| Beta blocker, n (%) | 15 (65) | 8 (50) | 7 (100) | 0.0520 |
| MRA, n (%) | 8 (34) | 6 (38) | 2 (29) | 1.0000 |
| Diuretics, n (%) | 11 (48) | 6 (38) | 5 (71) | 0.1930 |
| ARNI, n (%) | 2 (9) | 2 (13) | 0 (0) | 1.0000 |
| SGLT2I, n (%) | 5 (22) | 4 (25) | 1 (14) | 1.0000 |
| CCB, n (%) | 3 (13) | 0 (0) | 3 (19) | 0.5257 |
ACEI, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AST, aspartate aminotransferase; BMI, body mass index; CCB, calcium channel blocker; CK, creatine kinase; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; Hs-TnT, high-sensitivity troponin T; LDL-C, low-density lipoprotein cholesterol; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro–B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SGLT2, sodium-glucose co-transporter 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
